Uppsala, Sweden – February 17, 2015 – Orexo AB (publ) announces today that it has initiated the launch of a new higher ZUBSOLV tablet strength (8.6 mg/2.1 mg buprenorphine/naloxone CIII sublingual tablets). Furthermore, a new patent covering ZUBSOLV was issued in the U.S. The patent is listed in the Orange Book by U.S. Food and Drug Administration and expires in 2032. In December two new dosage strengths of ZUBSOLV were approved by the U.S. Food and Drug Administration (FDA). Orexo is now prepared to begin distribution and commence the launch of the 8.6 mg dosage, after having received final clearance of the REMS material. The updated REMS material is now published at www.BTODREMS.com. The new 8.6 mg dosage complements the existing dosage range of 5.7 mg/1.4 mg and 1.4 mg/0.36 mg tablets enabling more patients to receive their optimal dose in one tablet. The new ZUBSOLV dosage strength is based on the same advanced, proprietary sublingual tablet formulation used for the already launched ZUBSOLV tablets, providing higher bioavailability, fast dissolve time, small tablet size, and menthol flavor. The new dosage is expected to be available for patients in the first half of March. In January the United States Patent and Trademark Office issued a new patent protecting ZUBSOLV, U.S. Patent No. 8,940,330. The patent is the fourth patent listed in the Orange Book by the FDA covering ZUBSOLV and expires on September 18, 2032. “The continued development of the ZUBSOLV product range is a core element of Orexo’s strategy. We invest significant resources in developing the product through clinical research and pharmaceutical development to the benefit of patients suffering from opioid dependence. A solid patent protection platform is essential to enable these investments. With this latest patent, we gain additional confidence and commitment to our continued efforts to improve the treatment of opioid dependence.” said Nikolaj Sørensen, CEO and President of Orexo AB. For further information, please contact: Nikolaj Sørensen, President and CEO Tel: +46 (0)703-50 78 88, E-mail: ir@orexo.com About Orexo AB Orexo is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery. The company is commercializing its proprietary product, ZUBSOLV® sublingual tablets, for maintenance treatment of opioid dependence, in the United States. The ZUBSOLV sublingual tablet is a novel formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the US, EU and Japan. Orexo AB, with its headquarters in Sweden, is listed on Nasdaq Stockholm Exchange (STO: ORX) and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and HealthCap. For information about Orexo and ZUBSOLV, please visit www.orexo.com and www.zubsolv.com. Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Markets Act. The information was submitted for publication at 8:30am CET on February 17, 2015.
Orexo broadens ZUBSOLV® product range and announces newly
Top 10 Most Recent News Articles
Celebrating Leaders Advancing Type 1 Diabetes Research
Honoring Trailblazers in Type 1 Diabetes Research It's not every day that we get to shine a spotlight on the unsung heroes in the field of Type 1 Diabetes (T1D) research. Today, we pause to celebrate those who are doing the heavy lifting to make the lives of millions better. Breakthrough T1D, the name says it all, presented its prestigious awards to four titans of...
Continue Reading
Hitachi's Smart Energy Move: AI Capacity Boost Unveiled
Tackling Energy Challenges in Data Centers Data centers are struggling to keep up with the surging demand for computing power fueled by artificial intelligence, but Hitachi Vantara is flipping the script on how to handle it. Over in the Netherlands, they're working some serious tech magic by deploying a groundbreaking method to wrangle energy use and boost AI capability...
Continue Reading
OriginPoint Boosts Growth with $200M Lender Team
Mortgage Powerhouses Join Forces with OriginPoint It's not every day you see a $200 million mortgage team making a beeline for new pastures, but today's landscape seems ripe for such moves. Enter the We Fund LA team, led by mortgage veterans Daniel Arias and Ron Sequeira, as they align with OriginPoint Mortgage to scale new heights in Southern California. This isn't just...
Continue Reading
Elbit Systems Poised for Q3 2026 Earnings Reveal
Elbit Systems: A Strategic Player in Defense Here's what's going on with Elbit Systems Ltd. (NASDAQ:ESLT), the Israeli defense heavy hitter. They're gearing up to spill the beans on their Q3 financial results this November 17th. And for those of us keeping an eye on how defense contractors are adapting to today's chaotic geopolitical climate, this is a date you don't want...
Continue Reading
Nevada King's Gold Drilling Could Yield Big Returns
Unlocking Gold's Potential: A First Look Another day, another drill result, and this time it's Nevada King Gold Corp. (TSXV: NKG) (OTCQX: NKGFF) dropping the headlines. They've been playing in the dirt at their Atlanta Gold Mine Project in Nevada, unveiling numbers that might shake some of you out of your chairs. Peeking Into East Ridge and Silver Park Let's talk turkey,...
Continue Reading
Multiplier's Data Signals Global Hiring Evolution
Shaking Up the Global Hiring Playbook You think you know how hiring works globally? Think again. Based on data from a whopping 38,000 cross-border hires, Multiplier's latest Talent Trends has spilled some hot new beans on how companies are rethinking their talent acquisition strategies. This isn’t just some thumb-twiddling speculation either—it’s grounded in real...
Continue Reading
Venezuelan Crude Hits Texas: NABEP's Bold Move
Venezuelan Crude Docking in Texas Signals New Energy Dynamics Batten down the hatches, 'cause NABEP's Venezuelan crude has made a splashy arrival in Texas. We're talking 1 million barrels, folks, the first of its kind under a fresh U.S. deal. This ain't your grandpa's oil shipment from the Middle East that takes forever to get here—nope, this crude made a pit stop in...
Continue Reading
Backroads Invites Families: Adventures Boost Bookings by 20%
Rediscovering Family Time Through Adventure When was the last time a winter vacation got you this fired up? Backroads, the trailblazer in active getaways, is bucking the trend of typical holiday madness. Families are ditching the usual gift-giving grind for something way more memorable: experiences that blend action with bonding across generations. Big Numbers, Big...
Continue Reading
Etisalat Surges: Net Profit Soars 46% Amid Growth
Etisalat's Stellar Performance: A Deeper Dive When a company like Etisalat drops news of a whopping 46% increase in net profit year-over-year, you sit up and pay attention. Those numbers aren’t just a flash in the pan; they're the result of some serious strategic maneuvers and ripe market conditions. Etisalat isn't resting on its laurels, and their latest financials...
Continue Reading
mainelove Rides High With Double Gold and Growth
mainelove Shakes Up the Water Scene Well ain't that a splash? mainelove, the Maine-sourced water outfit, just snagged itself some shiny Double Gold hardware at the 2026 Water Choice Awards. Makes you raise a glass—or a can, I suppose—to see a local brand licking its chops over a win like this. It's not every day you hear a water company nailing it across state lines,...
Continue Reading
